About
Products
- Mirataz^® (mirtazapine transdermal ointment)
- Zimeta^™ (dipyrone injection)
Technology
- Veterinary Recombinant Biologics
- Manufacturing Process
Pipeline
Education
- KINections
Investors
News
- Press Releases
Contact Us
- Contact Us
- Careers
Menu

Test PI PDF Embed

You are here: Home / Test PI PDF Embed

Kindred Biosciences Announces Half-Life Extension Technology for Canine AntibodiesJanuary 8, 2020 - 4:04 pm
Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in DogsDecember 16, 2019 - 8:04 am
Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight LossDecember 12, 2019 - 9:09 am

Event: Kindred Biosciences to Present at Stifel Healthcare ConferenceNovember 14, 2019 - 4:11 pm
Event: Kindred Biosciences to Participate at Jefferies London Healthcare ConferenceNovember 14, 2019 - 4:11 pm
Event: Kindred Biosciences to Announce Third Quarter 2019 Financial ResultsOctober 28, 2019 - 8:35 am

$9.84

-0.43 (-4.19%)

KindredBio proudly supports
Rabies Free Africa